NSI-189 Phosphate
weak data
The Dose Guy’s verdictSep 1, 20263 sources
NSI-189 got further in the clinic than almost anything on this shelf, a real phase 2 in depression with real patients, and the primary endpoint missed at both doses. There are whispers in the secondary measures and a subgroup that looked promising, but the headline is a compound that had its shot at proof and came back with maybe. If you want a neurogenesis play with some clinical footing, this is the most tested option. Just know what “most tested” means here: tested and inconclusive.
What it is
A small molecule designed to promote hippocampal neurogenesis, the growth of new neurons in the region that handles memory and mood. Neuralstem built it for major depression, and the mechanism is real: in animal models and hippocampal slices, NSI-189 increases long-term potentiation and grows new cells. The question was never whether it does something in a dish. The question was whether swallowing a pill translates that into feeling better, and the trials gave a mixed answer.
On this shelf NSI-189 sits as the rare nootropic that actually ran human depression trials, which puts it ahead of most neighbors on clinical footing. The community runs it for cognition and mood, often stacking it alongside racetams, though the evidence for cognitive enhancement in healthy people does not exist.
What the research shows
More human data than most of this category, and a less satisfying story for it. NSI-189 reached a proper double-blind phase 2, and the result was a miss on the primary endpoint with scattered secondary signals.
Realistic protocols
If you are going to run NSI-189, 40 mg daily oral is the place to land. That was the dose with the most signal in the trial, and it is what most of the community runs. In the primary trial the 80 mg dose showed less signal than 40 mg, though a post-hoc analysis found 80 mg improved a depression subscale in a moderate-severity subgroup. More is not proven better for most people.
Take it in the morning. Effects reportedly build over weeks rather than hitting acutely, which fits a neurogenesis mechanism. If nothing has shifted after four to six weeks, it is probably not your compound. The community typically runs courses of eight to twelve weeks, then reassesses rather than staying on indefinitely.
Expect subtlety, not a switch flip. The people who report benefit describe a gradual lift in verbal fluency, mood floor, and working memory, not a stimulant-style rush. If you want a noticeable daily kick, this is the wrong tool.
One thing to know: the trials tested NSI-189 as monotherapy in depression. Most people running it are already on an SSRI or SNRI, and nobody has published data on the combination. If that is your situation, proceed carefully and pay attention to serotonergic overlap.
Side effects
The trials were clean. What shows up in practice:
